The Combined Effects of Sciemed Flex™ and Brain Function Squatemetry on Memory and Entrapment Neuropathy: A Neuroendocrinologic Concept Study. Alphonsus Ekwerike Science Medicine Research Institute, Dallas, TX .USA Print

Name :  Sciencemedicine

Date  :  14-Apr-2013


If you are the presenter of this abstract please show the QR code in your slide or poster (QR code contains this URL)



Sciemed Flex™ is a neuroendocrinologic-osteologic supplementary drug designed to promote mental health, systemic comfort, and joint flexibilities. Its formulatory ingredients are MSM (Methylsulfonalmethane), glucosamine Hcl, Chondroitin, manganese sulfate, Piper methysticum extract, totaling 1235 mg altogether, and Ascorbic acid 6 mg (100% DV) as the proprietary blend, with excepients of Calcium phosphate, maltodextrin, cellulose, extra refined vegetable oil, PEG 8000, and glycerol monostearate. Entrapment neuropathy is any mechanically induced irritative/inflammatory disorder that occurs within the neuromuscular anatomical landmarks that clinically manifest tingling, compressive pain, muscular weakness, paresthesias, etc. Entrpament neuropathy characterizes neuroendocrinologic deficits due to its compressive-inflammatory affections to the bones, muscles, nerves, blood vessels, and behavioral trends, etc. It obstructs blood flow, electrolytes, and neuropeptic functions, thereby inducing abnormal homeostasis, hypo or hypertonic metabolism, and painful mood swings. BrainFun™ Squatemetry is a cognitive profiling and therapeutic device that measures the short time, long time, calculative, abstract memories, etc.


 A total of 20 normal persons and 60 patients duly diagnosed routinely and with specialists investigations of x-ray, MRI, ECG, EEG, blood samples were studied. Orthopeadic and neurological examinations, respectively, were studied double blindly under four groups of 20 each, namely normasq, Entrap, Entrapflex, and Entrapflexsq. Sciemed flex tab 1 × 3 daily was given to the third and fourth groups only. Placebo 1 × 3 daily for 30 days was given to the normasq and Entrap groups. BrainFun™ Sqautemetry and physical therapy 3× weekly for 30 days applied to all. Altogether this study is for 90 days, with the second 30 days as recovery follow-up period. It is still ongoing. Pain assessment psychometry was used to infer neuralgia status.


The Entrapflexsq group showed quicker recovery rate and better cognitive prospective orientations than all. The Entrapflex group improved more than the Entrap group, while the normasq group showed better cognitive prospective orientation than the Entrap group and measured slightly above Entrapflex.


This result demonstrates that the combination of Sciemed flex tablets, BrainFun™ Sqautemetry, and physical therapy promote mental health, entrapment release, joint flexibility, and general well being, and shows that pain inhibits cognition.

Citation & Copyright © 2009 The American Society for Experimental NeuroTherapeutics, Inc. Abstract #6.                      Published by Elsevier B.V. All rights reserved.